Symptoms illustrated.
Not an actual patient.
Itch Relief
ITCH IMPROVEMENT AT WEEK 4 WITH RESULTS OBSERVED WITHIN 24 HOURS
TWICE AS MANY PATIENTS ACHIEVED ITCH IMPROVEMENT AT WEEK 4 WITH ZORYVE2
Secondary endpoint
Nearly2x
as many patients achieved WI-NRS Success at Week 4 with ZORYVE (32%; n=542) vs with vehicle (17%; n=271)2*
Daily WI-NRS2
Greater itch improvement observed within 24 HOURS after first application with ZORYVE as compared to vehicle2*
Data are pooled analyses of the INTEGUMENT-1 and -2 studies.
*Daily WI-NRS was a prespecified exploratory endpoint. Patients were asked to keep a daily diary logging itch symptoms and their severity. Day 1 represents baseline, first application. Evaluated in all patients, not just those with baseline WI-NRS score ≥4. Pooled analysis P-values are nominal.
LS = least squares. WI-NRS = Worst Itch Numeric Rating Scale. WI-NRS Success = ≥4-point improvement for patients with a baseline score ≥4. WI-NRS: 0 (no itch) to 10 (worst imaginable itch).
BASELINE
vIGA-AD = 3
WEEK 4
vIGA-AD = 0
Actual clinical trial patient